Clinical trials: Hepatic Fibrosis
Nonalcoholic Steatohepatitis
AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH)
The AURORA study will be conducted to confirm the efficacy and safety of cenicriviroc (CVC) for the treatment of liver fibrosis in adult participants with NASH.
- Trial name
- AURORA (NCT03028740)
- Testing
- Cenicriviroc
- Where
- 346 sites in United States, Australia and 26 more
- Volunteers
- 1,778 people
- Sponsor
- Tobira Therapeutics, Inc.
Liver Cirrhoses
Preoperative Portal and Splanchnic Flow Measurement Using MRI
This study aims to assess the alteration of portal and splanchnic flow using MRI after liver transplantation in patients with splenomegaly or splenic varix.
- Trial name
- NCT03868397
- Testing
- Liver MRI
- Where
- South Korea
- Volunteers
- 12 people
- Sponsor
- Seoul National University Hospital
Liver Cirrhosis, Portal Hypertension
Value of Von Willebrand Factor in Portal Hypertension
In patients with liver cirrhosis elevated levels of von Willebrand factor antigen (vWF-Ag) are found frequently but the clinical significance is unclear.
- Trial name
- NCT01358123
- Where
- Austria
- Volunteers
- 300 people
- Sponsor
- Medical University of Vienna
Portal Vein Thrombosis, Liver Cirrhosis
Compare the Efficacy and Safety of Dabigatran and Enoxaparin in Patients With Portal Vein Thrombosis With Cirrhosis
Portal vein thrombosis (PVT) is prevalent among patients with cirrhosis, and its prevalence rises with the severity of liver disease.
- Trial name
- NCT06818279
- Testing
- Dabigatran, Enoxaparin
- Where
- India
- Volunteers
- 120 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Liver Fibrosis, Fatty Liver
Comparison of iLivTouch and FibroScan for the Assessment of Liver Fibrosis and Steatosis in Adult Patients in the US
This is a multi-center, cross-sectional, and prospective study that will recruit patients from multiple hospitals or outpatient clinics in the USA to the comparison of iLivTouch and FibroScan for the assessment of liver fibrosis…
- Trial name
- NCT06051669
- Testing
- iLivTouch, FibroScan
- Where
- 4 sites in United States
- Volunteers
- 418 people
- Sponsor
- New Discovery LLC
HIV Infection, Hepatitis C
Improving Fibrosis Outcomes With Metformin
This study will evaluate the role of Metformin on liver fibrosis in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance receiving DAA HCV treatment.
- Trial name
- NCT02306070
- Testing
- Metformin, No metformin treatment
- Where
- Canada
- Sponsor
- Ottawa Hospital Research Institute
Ascites
Sodium Restriction in the Management of Cirrhotic Ascites
To determine the relationship between degree of sodium restriction and dietary compliance with clinical outcome of diuresis of portal hypertensive ascites in cirrhotic patients from a county hospital population.
- Trial name
- NCT00548366
- Testing
- Sodium restriction
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- University of Texas Southwestern Medical Center
Type 2 Diabetes, Fatty Liver
Silymarin Effects on Fatty Liver in Type 2 Diabetics
This nine-month prospective clinical trial evaluated the effects of adding a daily oral dose of 480 mg of silymarin (milk thistle) to standard multi-drug therapy in 120 adult patients with Type 2 diabetes.
- Trial name
- NCT07871370
- Testing
- Silymarin (Silybum marianum)
- Where
- Iraq
- Volunteers
- 120 people
- Sponsor
- University of Mosul
Primary Biliary Cholangitis, Liver Cirrhosis
Austrian PBC Registry
The goal of this registry is to better understand how primary biliary cholangitis develops over time, including the role of disease-related biomarkers, complications of the disease, and symptom burden.
- Conditions
- Primary Biliary Cholangitis, Liver Cirrhosis, Portal Hypertension
- Trial name
- PBC-AUT (NCT07598669)
- Where
- 11 sites in Austria
- Volunteers
- 500 people
- Sponsor
- Medical University of Vienna
Hepatic Impairment
A Single and Repeat Dose Trial in Participants With Hepatic Impairment
This study is a a single (open-label) and repeat dose (randomised, placebo controlled) trial to assess the safety, tolerability and pharmacokinetics of GB1211 (Gal-3 inhibitor) in participants with hepatic impairment (Child Pugh…
- Trial name
- NCT05009680
- Testing
- GB1211
- Where
- 4 sites in Bulgaria
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Galecto Biotech AB
Type2diabetes
Effect of SGLT-2 Inhibitors in Patients With T2DM and Moderate to Severe Liver Fibrosis
This retrospective study will be of 12 months duration where 40 T2DM patients coming to FORTIS C-DOC hospital in OPD with F3 fibrosis will be included in the study.
- Trial name
- NCT05943899
- Where
- India
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Diabetes Foundation, India
Hepatic Impairment
Pharmacokinetics of TD-4208 in Patients With Moderate Hepatic Impairment
This multiple-center, nonrandomized, open label, parallel group, single dose study will be conducted in male and female subjects with normal hepatic function or moderate (Child-Pugh Class B) hepatic impairment to evaluate the…
- Trial name
- NCT02581592
- Testing
- TD-4208
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Mylan Inc.
NAFLD, Alcohol-Related Disorder
Screening in Primary Care of Advanced Liver Fibrosis in NAFLD and/or Alcoholic Patients (IMPROVE Study)
The main objective is to determine the performance of the simple eLIFT blood test for advanced liver fibrosis screening in NAFLD and/or alcoholic patients in primary care.
- Conditions
- NAFLD, Alcohol-Related Disorder, Liver Fibrosis
- Trial name
- IMPROVE (NCT04146636)
- Testing
- e-LIFT
- Where
- France
- Volunteers
- 282 people
- Sponsor
- University Hospital, Angers
Liver Pathology
Screening of Patients With Hepatic Fibrosis or Cirrhosis B and C
Regardless of its etiology (chronic hepatitis B or C, alcohol consumption, metabolic steatohepatitis, hemochromatosis, autoimmune liver disease), cirrhosis is a real public health issue.
- Trial name
- DEP-CB (NCT06755632)
- Testing
- TROD (rapid diagnostic orientation test) and FibroScan®
- Where
- 2 sites in France
- Volunteers
- 600 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cirrhosis
Breath Test to Assess Hepatic Metabolic Reserve and to Predict Hepatic Decompensation in Cirrhotics
The three objectives of this trial are: 1. To demonstrate that a decline in hepatic metabolic function as measured by BreathID will correlate with changes in CTP and MELD scores in patients with cirrhosis. 2.
- Trial name
- NCT00375011
- Where
- 3 sites in United States, Israel
- Volunteers
- 200 people
- Sponsor
- Meridian Bioscience, Inc.
NASH, NAFLD
Digoxin In NASH (CODIN)
Nonalcoholic steatohepatitis (NASH) is a severe subtype of nonalcoholic fatty liver disease (NAFLD) which affects 1 in 3 Americans.
- Conditions
- NASH, NAFLD, MASH - Metabolic Dysfunction-Associated Steatohepatitis, Mash
- Trial name
- CODIN (NCT06588699)
- Testing
- Digoxin
- Where
- 2 sites in United States
- Volunteers
- 144 people
- Sponsor
- Yale University
Portal Hypertension, Clinically Significant Portal Hypertension
Assessment of Portal Hypertension With Multiparametric MRI
The purpose of this study is to determine whether new multiparametric magnetic resonance imaging (MRI) methods (including diffusion-weighted MRI, dynamic contrast-enhanced MRI, MR elastography and phase-contrast imaging) can be…
- Trial name
- NCT03436550
- Testing
- mpMRI, ARFI US
- Where
- United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
Cirrhosis
EYE-Mobile TRACKer IN the Diagnosis of Minimal Hepatic Encephalopathy
Hepatic encephalopathy (HE) corresponds to the neurological or the neuropsychological symptoms caused by an acute or chronic liver disease and/or porto-systemic shunt.
- Trial name
- EyeMTRACKIN-HE (NCT03732118)
- Testing
- Eye-tracker Mobile EBT
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Esophageal Neoplasms, Cirrhosis
Endoscopic Resection of Early Esophageal Tumors in the Context of Cirrhosis or Portal Hypertension
Cirrhotic patients may be at high risk for esophageal cancer. Endoscopic resection is the standard treatment for superficial tumors.
- Conditions
- Esophageal Neoplasms, Cirrhosis, Portal Hypertension
- Trial name
- NCT04994548
- Testing
- Endosocpic resection of early esophageal tumor
- Volunteers
- 112 people
- Sponsor
- Central Hospital, Nancy, France
Liver Cirrhosis, HCC - Hepatocellular Carcinoma
Effect of Laparoscopic Hepatectomy Combined With Splenectomy on Hepatic Functional Reserve and Immune Function
Splenectomy may relieve hypersplenism, reverse liver fibrosis, improve hepatic functional reserve, and reshape the systemic antitumor immune milieu by removing the source of negative immunomodulation.
- Conditions
- Liver Cirrhosis, HCC - Hepatocellular Carcinoma, Hypersplenism
- Trial name
- LHCS-HFRI (NCT07811687)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Northern Jiangsu People's Hospital